Unique ID issued by UMIN | UMIN000010478 |
---|---|
Receipt number | R000012128 |
Scientific Title | Combined Aspirin Study for Mechanical Prosthetic Valve in Kyushu and Ryukyu by Inter-University Hospital Network (ASPIRIN trial) |
Date of disclosure of the study information | 2013/04/15 |
Last modified on | 2021/10/21 21:19:23 |
Combined Aspirin Study for Mechanical Prosthetic Valve in Kyushu and Ryukyu by Inter-University Hospital Network (ASPIRIN trial)
ASPIRIN trial
Combined Aspirin Study for Mechanical Prosthetic Valve in Kyushu and Ryukyu by Inter-University Hospital Network (ASPIRIN trial)
ASPIRIN trial
Japan |
Valvular heart disease
Cardiology | Cardiovascular surgery |
Others
NO
Comparison of thromboembolic and hemorrhagic events between Japanese patients with mechanical prosthetic valve treated by warfarin alone and those treated by combined warfarin and aspirin.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
1) Atherosclerotic events, including stroke, TIA, ischemic heart disease, systemic embolism, peripheral artery disease, and valve thrombosis.
2) Cardiovascular death
1) All cause death
2) Hemorrhagic events, including intracranial bleeding, gastrointestinal bleeding, bleeding requiring hospitalization and/or blood transfusion, and other significant bleeding
3) gastroduodenal ulcer
Observational
20 | years-old | <= |
Not applicable |
Male and Female
The inclusion criteria were implantation of a mechanical prosthetic valve, age over 20 years, and provided informed consent.
1) Contraindications to anticoagulant therapy
2) Pregnant patients
3) Feeding patients
4) Patients who were considered not adequate to be included in the study by an attending physician
500
1st name | |
Middle name | |
Last name | Yutaka Otsuji |
University of Occupational and Environmental Health, Japan, School of Medicine
The Second Department of Internal Medicine
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
093-603-1611
otsujiy@med.uoeh-u.ac.jp
1st name | |
Middle name | |
Last name | Yuki Tsuda |
University of Occupational and Environmental Health, Japan, School of Medicine
The Second Department of Internal Medicine
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
093-691-7250
yoshimikamio@med.uoeh-u.ac.jp
Yutaka Otsuji
Japan Society for the Promotion of Science
Japan
NO
大分大学医学部附属病院(大分県)、鹿児島大学医学部・歯学部附属病院(鹿児島県)、九州大学医学部附属病院(福岡県)、熊本大学医学部附属病院(熊本県)、久留米大学病院(福岡県)、佐賀大学医学部附属病院(佐賀県)、産業医科大学病院(福岡県)、長崎大学附属病院(長崎県)、福岡大学病院(福岡県)、宮崎大学附属病院(宮崎県)、琉球大学医学部附属病院(沖縄県)
2013 | Year | 04 | Month | 15 | Day |
Unpublished
No longer recruiting
2013 | Year | 03 | Month | 31 | Day |
2012 | Year | 12 | Month | 19 | Day |
2013 | Year | 06 | Month | 01 | Day |
2021 | Year | 06 | Month | 30 | Day |
2021 | Year | 10 | Month | 10 | Day |
2021 | Year | 10 | Month | 31 | Day |
2021 | Year | 12 | Month | 31 | Day |
1) non-randomized prospective observational study
2) Selection of treatment (warfarin alone therapy (W group) or warfarin + low dose aspirin therapy (W + A group)) was left to the attending physicians, who were informed that either treatment allowed.
3) Anticoagulant therapy
The daily dose of warfarin was based on the PT-INR. The target PT-INR level was 1.6 to 3.0. PT-INR will be measured every 2 to 4 weeks after hospital discharge.
4) Anti-platelet therapy
Patients of W + A group will receive 100mg of aspirin per day orally.
5) Follow-up
The patients will be monitored routinely for outcome events during hospitalization and during follow-up at 6 months and 1, 2, 3, 4, 5 years postoperatively.
2013 | Year | 04 | Month | 12 | Day |
2021 | Year | 10 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012128